X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GLENMARK PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GLENMARK PHARMA DR. REDDYS LAB/
GLENMARK PHARMA
 
P/E (TTM) x 31.5 25.3 124.7% View Chart
P/BV x 3.4 4.0 85.4% View Chart
Dividend Yield % 0.8 0.3 255.6%  

Financials

 DR. REDDYS LAB   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
GLENMARK PHARMA
Mar-17
DR. REDDYS LAB/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788993 280.8%   
Low Rs1,902729 260.8%   
Sales per share (Unadj.) Rs860.8325.5 264.4%  
Earnings per share (Unadj.) Rs57.139.3 145.2%  
Cash flow per share (Unadj.) Rs122.048.7 250.7%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.90.2 367.3%  
Book value per share (Unadj.) Rs757.7159.2 475.9%  
Shares outstanding (eoy) m165.91282.17 58.8%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.72.6 103.0%   
Avg P/E ratio x41.121.9 187.5%  
P/CF ratio (eoy) x19.217.7 108.6%  
Price / Book Value ratio x3.15.4 57.2%  
Dividend payout %35.05.1 688.6%   
Avg Mkt Cap Rs m389,034242,991 160.1%   
No. of employees `00023.513.0 181.4%   
Total wages/salary Rs m32,14916,408 195.9%   
Avg. sales/employee Rs Th6,070.87,083.9 85.7%   
Avg. wages/employee Rs Th1,366.61,265.4 108.0%   
Avg. net profit/employee Rs Th402.5855.1 47.1%   
INCOME DATA
Net Sales Rs m142,81091,857 155.5%  
Other income Rs m1,552374 415.4%   
Total revenues Rs m144,36292,230 156.5%   
Gross profit Rs m23,51220,367 115.4%  
Depreciation Rs m10,7722,644 407.5%   
Interest Rs m7882,373 33.2%   
Profit before tax Rs m13,50415,724 85.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m4,3803,827 114.5%   
Profit after tax Rs m9,46811,088 85.4%  
Gross profit margin %16.522.2 74.3%  
Effective tax rate %32.424.3 133.3%   
Net profit margin %6.612.1 54.9%  
BALANCE SHEET DATA
Current assets Rs m104,98468,746 152.7%   
Current liabilities Rs m68,93827,027 255.1%   
Net working cap to sales %25.245.4 55.6%  
Current ratio x1.52.5 59.9%  
Inventory Days Days7485 87.5%  
Debtors Days Days10496 108.4%  
Net fixed assets Rs m104,38524,132 432.6%   
Share capital Rs m830282 294.1%   
"Free" reserves Rs m124,88644,643 279.7%   
Net worth Rs m125,71644,925 279.8%   
Long term debt Rs m25,08945,363 55.3%   
Total assets Rs m225,443117,639 191.6%  
Interest coverage x18.17.6 237.8%   
Debt to equity ratio x0.21.0 19.8%  
Sales to assets ratio x0.60.8 81.1%   
Return on assets %4.511.4 39.8%  
Return on equity %7.524.7 30.5%  
Return on capital %9.719.1 50.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62356,152 129.3%   
Fx outflow Rs m18,9168,084 234.0%   
Net fx Rs m53,70748,068 111.7%   
CASH FLOW
From Operations Rs m18,0306,574 274.2%  
From Investments Rs m-14,883-7,124 208.9%  
From Financial Activity Rs m-4,4405,432 -81.7%  
Net Cashflow Rs m-1,2361,992 -62.0%  

Share Holding

Indian Promoters % 25.5 48.3 52.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 6.9 78.3%  
FIIs % 35.3 34.4 102.6%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 56,727 133.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   WOCKHARDT LTD.  FULFORD INDIA  MERCK LTD  BIOCON LTD  UNICHEM LAB  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 21, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - FRESENIUS KABI ONCO. COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS